RE: CFO to CoE2 Dec 2024 09:29
P1b will start soon (CC hasn't missed an objective set yet) and we will have emerging data on 2 orphan indications and TNBC in H1. Given the tumours are sensitive to dox and the tumours will not be refractory the results (given we know mechanism of action proven) will surely be stunning and there will surely be lots of optionality for deals. Finally! The Peel note said finance will be linked to data so I assume emerging P1b will be a catalyst and who knows what will happen before re sale of DX, new CFO, intention to list on NASDAQ. An interesting few weeks and months for sure. Also recruitment will be a lot quicker as no 3 plus 3 and the superb results so far and SAB on baord will mean recruitment go go go